- Home
- GMAB vs PCTY Comparison
GMAB vs PCTY Comparison
Compare GMAB & PCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PCTY
- Stock Information
- Founded
- GMAB 1999
- PCTY 1997
- Country
- GMAB Denmark
- PCTY United States
- Employees
- GMAB N/A
- PCTY N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PCTY Computer Software: Prepackaged Software
- Sector
- GMAB Health Care
- PCTY Technology
- Exchange
- GMAB Nasdaq
- PCTY Nasdaq
- Market Cap
- GMAB 12.8B
- PCTY 10.4B
- IPO Year
- GMAB N/A
- PCTY 2014
- Fundamental
- Price
- GMAB $19.88
- PCTY $201.04
- Analyst Decision
- GMAB Buy
- PCTY Strong Buy
- Analyst Count
- GMAB 9
- PCTY 19
- Target Price
- GMAB $39.17
- PCTY $223.21
- AVG Volume (30 Days)
- GMAB 1.5M
- PCTY 401.5K
- Earning Date
- GMAB 05-08-2025
- PCTY 05-01-2025
- Dividend Yield
- GMAB N/A
- PCTY N/A
- EPS Growth
- GMAB 85.27
- PCTY 16.86
- EPS
- GMAB 17.68
- PCTY 4.01
- Revenue
- GMAB $3,135,137,804.00
- PCTY $1,551,771,000.00
- Revenue This Year
- GMAB $17.69
- PCTY $13.72
- Revenue Next Year
- GMAB $14.81
- PCTY $10.22
- P/E Ratio
- GMAB $1.12
- PCTY $50.14
- Revenue Growth
- GMAB 51.92
- PCTY 14.63
- 52 Week Low
- GMAB $17.24
- PCTY $129.94
- 52 Week High
- GMAB $30.41
- PCTY $223.80
- Technical
- Relative Strength Index (RSI)
- GMAB 48.84
- PCTY 63.41
- Support Level
- GMAB $18.89
- PCTY $197.60
- Resistance Level
- GMAB $19.67
- PCTY $201.97
- Average True Range (ATR)
- GMAB 0.49
- PCTY 5.48
- MACD
- GMAB -0.12
- PCTY 1.40
- Stochastic Oscillator
- GMAB 34.61
- PCTY 95.70
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PCTY Paylocity Holding Corporation
Paylocity is a provider of payroll and human capital management solutions servicing small- to midsize clients in the United States. The company was founded in 1997 and targets businesses with 10-5,000 employees and services about 39,000 clients as of fiscal 2024. Alongside core payroll services, Paylocity offers HCM solutions such as time and attendance and recruiting software as well as workplace collaboration and communication tools.